260 related articles for article (PubMed ID: 26185196)
1. Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors.
Serrano JM; González I; Del Castillo S; Muñiz J; Morales LJ; Moreno F; Jiménez R; Cristóbal C; Graupner C; Talavera P; Curcio A; Martínez P; Guerra JA; Alonso JJ
Oncologist; 2015 Aug; 20(8):864-72. PubMed ID: 26185196
[TBL] [Abstract][Full Text] [Related]
2. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
[TBL] [Abstract][Full Text] [Related]
3. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
[TBL] [Abstract][Full Text] [Related]
4. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
5. Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines.
Mata Caballero R; Serrano Antolín JM; Jiménez Hernández RM; Talavera Calle P; Curcio Ruigómez A; Del Castillo Arrojo S; Graupner Abad C; Cristóbal Varela C; Alonso Martín JJ
Cardiol J; 2022; 29(2):228-234. PubMed ID: 32329038
[TBL] [Abstract][Full Text] [Related]
6. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G
Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
8. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy.
Klein R; Nadouri D; Osler E; Johnson C; Dent S; Dwivedi G
Nucl Med Commun; 2019 Jan; 40(1):22-29. PubMed ID: 30418380
[TBL] [Abstract][Full Text] [Related]
9. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction.
Minotti G; Salvatorelli E; Reggiardo G; Mangiacapra F; Camilli M; Menna P
J Pharmacol Exp Ther; 2022 Jun; 381(3):266-273. PubMed ID: 35332076
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal.
Minotti G; Menna P; Camilli M; Salvatorelli E; Reggiardo G
J Pharmacol Exp Ther; 2021 Feb; 376(2):231-239. PubMed ID: 33168644
[TBL] [Abstract][Full Text] [Related]
12. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling.
Mizia-Stec K; Gościńska A; Mizia M; Haberka M; Chmiel A; Poborski W; Gąsior Z
Kardiol Pol; 2013; 71(7):681-90. PubMed ID: 23907900
[TBL] [Abstract][Full Text] [Related]
15. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
[TBL] [Abstract][Full Text] [Related]
16. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
17. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
Garrone O; Crosetto N; Lo Nigro C; Catzeddu T; Vivenza D; Monteverde M; Merlano M; Feola M
Cardiovasc Toxicol; 2012 Jun; 12(2):135-42. PubMed ID: 22189487
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
19. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
20. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]